YourLawyer.com 1-800-LAW-INFO (1-800-529-4636)

Byetta


AddThis Social Bookmark Button

Byetta Pancreatitis Lawyers

Keywords:  Byetta Lawyer Pancreatitis  Side Effects

The lawyers and attorneys at our firm are currently offering free case evaluations to the victims of Byetta side effects. Byetta has been linked to the onset of acute pancreatitis, as well as hemorrhagic and necrotizing pancreatitis. At least two people have died as a result of Byetta-associated pancreatitis. If you or a loved one were diagnosed with pancreatitis while taking Byetta for type 2 diabetes, please contact one of our Byetta pancreatitis lawyers as soon as possible to protect your rights.

Byetta is made by Amylin Pharmaceuticals Inc, and marketed jointly by Amylin and Eli Lilly, & Co. The drug was approved by the Food & Drug Administration (FDA) in 2005 to help type 2 diabetics better control blood sugar when other drugs were not adequate. The twice-daily injection is a synthetic form of a lizard hormone that boosts the production of insulin.

More than 700,000 patients worldwide have used Byetta since it was launched. While diabetics are more vulnerable to developing pancreatitis than those without the disease, it is becoming apparent that this drug increases that risk. It is clear that Amylin and Eli Lilly did not subject this medication to adequate safety testing. Our Byetta pancreatitis lawyers will work hard to make sure that these companies are held accountable for their negligence.

In August 2008, the FDA said it was working with Amylin to add stronger and more prominent warnings on the product label about the risk of acute hemorrhagic or necrotizing pancreatitis. However, the FDA did not indicate if such warnings would take the form of a "black box", the agency's most urgent safety alert. Our Byetta pancreatitis lawyer believe that Amylin should have added such a warning much earlier, when the drug's association with pancreatitis became apparent.

FDA Byetta Warnings

Since October 2007, the FDA has issued two warnings regarding Byetta and acute pancreatitis, as well as hemorrhagic and necrotizing pancreatitis. Pancreatitis is an inflammation of the pancreas that can cause bleeding, tissue damage and infection. Severe cases of pancreatitis can lead to the release of toxins and enzymes into the blood stream that can injure the heart, lungs, kidneys or other organs. In some instances, pancreatitis can be fatal.


In October 2007, the FDA issued a health alert after it received 30 reports of Byetta patients who developed acute pancreatitis. Of those, 5 later suffered from kidney failure. Six patients experienced the onset or worsening of symptoms after their dosage of Byetta was increased from 5 milligrams twice daily to 10 milligrams twice daily. And according to the FDA, pancreatitis symptoms in 22 patients subsided or improved once they quit taking Byetta.

Acute pancreatitis comes on suddenly, and is characterized by mild to severe pain in the upper abdomen that may radiate to the back and occasionally to the chest. The pain can be nearly constant for hours or days, and will become worse if a patient drinks alcohol or eats. Bending forward or curling into a fetal position may provide temporary relief. The Byetta pancreatitis lawyers at our firm know how serious and debilitating acute pancreatitis is, and we will make sure that the victims of this dangerous drug receive the compensation they deserve.

At the time of the 2007 alert, the FDA said that Amylin had agreed to include information about acute pancreatitis in the PRECAUTIONS section of the Byetta label. However, as of August 2008, that information still was not included on the Byetta package insert.

In August 2008, the FDA issued its second pancreatitis warning for Byetta. At the time, the agency said that it had received reports of 6 cases of hemorrhagic or necrotizing pancreatitis in patients taking Byetta since its October alert. All patients required hospitalization, two patients died and four patients were recovering at time of reporting.  Byetta was discontinued in all 6 cases.

Hemorrhagic pancreatitis is inflammation that involves bleeding. Necrotizing pancreatitis occurs when the inflamed pancreas destroys itself. There are no signs or symptoms that distinguish hemorrhagic or necrotizing pancreatitis associated with Byetta from the less severe form of pancreatitis.

The FDA alert said that Byetta should be discontinued if pancreatitis is suspected. The FDA also said doctors should consider antidiabetic therapies other than Byetta in patients with a history of pancreatitis. Patients taking Byetta should seek prompt medical care if they experience unexplained persistent severe abdominal pain which may or may not be accompanied by vomiting. 


Legal Help Byetta Pancreatitis Victims

If you or a loved one suffered from acute pancreatitis, necrotizing pancreatitis or hemorrhagic pancreatitis that may have been caused by Byetta, you have valuable legal rights. Please fill out our online form or call 1-800 LAW INFO (1-800-529-4636) to discuss your case with an experienced Byetta pancreatitis lawyer.


ByettaRSS Feed

Flagging Byetta Sales Force Job Cuts at Amylin

Nov 12, 2008 | Parker Waichman Alonso LLP
Safety concerns surrounding the diabetes drug Byetta have slowed its sales, forcing Amylin Pharmaceuticals to cut a quarter of its work force. Byetta, which is jointly marketed by Amylin and Eli Lilly, was approved by the Food & Drug Administration (FDA) in 2005 to help type 2 diabetics better control blood sugar when other drugs were not adequate. The twice-daily injection is a synthetic form of a lizard hormone that boosts the production of insulin. Insulin is vital to controlling blood...

Long-Acting Byetta Faces Approval Obstacles

Nov 5, 2008 | Parker Waichman Alonso LLP
A new version of Byetta, a diabetes drug made by Amylin Pharmaceuticals Inc. and Eli Lilly & Co., isn't going to be approved by the Food & Drug Administration (FDA) anytime soon.  Amylin said yesterday in a regulatory filing that data for the new Byetta didn't satisfy the FDA's  standards.The original Byetta was approved by the FDA in 2005 to help type 2 diabetics better control blood sugar when other drugs were not adequate. The twice-daily injection is a synthetic form of a...

New Diabetes Drugs More Expensive, But Not Always Better

Oct 28, 2008 | Parker Waichman Alonso LLP
A new report has found that the cost for treating diabetes has skyrocketed, despite inconclusive evidence that newer, more expensive treatments provide added benefits to patients. In 2002, diabetes accounted for more than 10 percent of U.S. health-care expenditures, and that number is expected to increase as the number of people with type 2 diabetes grows.   According to the study conducted by researchers at the University of Chicago and Stanford University, between 2001 and 2007,...

Amylin Releases Questionable Byetta Study in Attempt to Take Focus From Pancreatitis Risk

Sep 10, 2008 | Parker Waichman Alonso LLP
Byetta maker, Amylin Pharmaceuticals, is trying to save the diabetes drug's reputation by touting a new study that shows it to be more effective than a rival medication.  But at least one drug industry analyst has characterized the research - which compares Byetta to Januvia - as a "marketing study" meant to focus attention away from Byetta's association with pancreatitis.Byetta was approved by the Food & Drug Administration (FDA) in 2005 to help type 2 diabetics better...

Byetta Linked to More Deaths

Aug 27, 2008 | Parker Waichman Alonso LLP
Byetta has been implicated in six deaths, four more than federal regulators reported last week.  The additional deaths were revealed late yesterday during a conference call conducted by Amylin Pharmaceuticals Inc. and Eli Lilly & Co, the co-marketers of the diabetes drugs.  The companies did report the other four deaths to the Food & Drug Administration (FDA), but the agency did not make those fatalities public in last week's announcement.No definite relationship between...

More Byetta News

Defective Drugs
* Denotes required field.

Title

* First Name

* Last Name

* Email Address

* Phone Number

Cell Phone Number

Office Phone Number

Street Address

Apartment/Suite

City

State

Zip Code

Please provide the best method and times to contact you:

Date of birth of person injured
(mm-dd-yyyy):

Name of drug:

Date you started taking the drug (mm-yyyy):

Date you stopped taking the drug (mm-yyyy):

Please describe any side effects:

Other Info:

No Yes, I agree to the Parker Waichman Alonso LLP disclaimers.Click here to review all.

Yes, I would like to receive the Parker Waichman Alonso LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Home | Defective Drugs | Medical Devices | Toxic Substances | Accidents | Product Liability | Malpractice | Diseases
Nursing Home Negligence | Food Poisoning | Other Topics | Contact
Statement of Clients' Rights | Site Map | ReNu with MoistureLoc | Vioxx | Mesothelioma | Permax | Dostinex | Composix Kugel Mesh X Large Patch
Ortho Evra | Fosamax | Personal Injury Lawyer | Fusarium Keratitis | Stevens Johnson Syndrome

© 2002-2008 YourLawyer.com. All Rights Reserved.

Please note that you are not considered a client until you have signed a retainer agreement and your case has been accepted by us.
Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Attorney Advertising

Parker Waichman Personal Injury News